4-十五烷基苯胺 | 68777-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-十五烷基苯胺
• 英文名称: p-pentadecylaniline
• 英文别名: 4-Pentadecylaniline；4-pentadecylaniline
• CAS: 68777-67-3
• 化学式: C₂₁H₃₇N
• 分子量: 303.531
• InChiKey: YDDQQMZUTLFLEH-UHFFFAOYSA-N

物化性质

• 沸点：
  422.0±14.0 °C(Predicted)
• 密度：
  0.895±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  22
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-十五烷基苯胺 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 16.0h， 生成 N-methyl-4-pentadecylaniline
  参考文献：
  名称：

  COMPOUND FOR TREATING CARTILAGE DISORDERS

  摘要：

  公开号：

  EP2740724B1

文献信息

• Effects of doped dialkylazobenzenes on helical pitch of cholesteric liquid crystal with medium molecular weight: utilisation for full-colour image recording
  作者：Masaya Moriyama、Soyoung Song、Hiro Matsuda、Nobuyuki Tamaoki

  DOI：10.1039/b009892m

  日期：——

  The effects of small amounts of achiral photochromic dopants, 4,4′-di-n-alkylazobenzenes, with various lengths of substituted alkyl chain (CnH2n + 1 ∶ n = 4, 7, 11, 12, 13, 14, 15, 16) on the helical pitch of a cholesteric liquid crystal (CLC) with ca. 1000 molecular weight were investigated in order to utilise the cholesteric reflected colour of these combinations for a rewritable colour image recording. The (E)-azobenzenes (~2 wt%) in the host CLC induced pitch changes dependent on temperature, the concentration of the azobenzenes and the length of substituted alkyl chain on the azobenzenes. In the low region of the cholesteric temperature (below 100 °C), some (E)-azobenzenes remarkably lengthened the pitch. Contrary to this, upon irradiation, E–Z photoisomerization of all the azobenzenes in the CLC phase induced consecutive pitch shortenings in response to the formation of the Z isomers. The changed pitch (reflected colour) could be fixed in cholesteric glassy solids. In the glassy solid state, the photo and thermal isomerization of the azobenzenes could not influence the cholesteric pitch any longer, therefore, the colour was stably stored. However, since the molecular arrangement of the CLC and the conformation of the doped azobenzenes completely returned to the initial state upon re-heating to isotropic temperatures, the stored colour could be easily erased. Based on these fundamental investigations, it is suggested that the mixed systems of the medium-molecular-weight CLCs and the 4,4′-dialkylazobenzenes will be effective materials for a rewritable full-colour image recording in a photon mode.

  少量非手性光致变色掺杂剂的影响， 4,4′-二正烷基偶氮苯，具有不同长度的取代基 烷基链 (CnH2n + 1∶n = 4, 7, 11, 12, 13, 14, 15, 16) 在胆甾型液体的螺距上 晶体（CLC）约。研究了1000个分子量 为了利用这些组合的胆甾醇反射颜色 用于可重写的彩色图像记录。 (E)-偶氮苯 (~2 wt%) 在宿主 CLC 中引起的音调变化取决于温度、浓度 偶氮苯和偶氮苯上取代的烷基链的长度。 在胆甾温度较低的区域（100°C以下）， 一些(E)-偶氮苯显着延长了螺距。与此相反 在照射下，所有偶氮苯发生 E-Z 光致异构化 在 CLC 阶段引起连续音高缩短以响应 Z异构体的形成。改变的音高（反射颜色） 可以固定在胆甾型玻璃状固体中。在玻璃态固态下， 偶氮苯的光异构化和热异构化不会影响 胆甾醇沥青不再存在，因此颜色可以稳定保存。然而， 由于 CLC 的分子排列和掺杂的构象 偶氮苯重新加热至各向同性后完全恢复到初始状态 温度，存储的颜色可以很容易地被擦除。基于这些基本 研究表明，中等分子量的混合体系 CLCs和4,4'-二烷基偶氮苯将成为有效的材料 以光子模式记录可重写的全彩图像。
• Compound for treating cartilage disorders
  申请人：Obitsu Tetsuo

  公开号：US09085523B2

  公开（公告）日：2015-07-21

  The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders. Since a suspension produced using this compound can be injected without requiring the incision of the affected part, it can reduce the burden on patients, and is extremely useful as a medicinal agent.

  本发明提供了一种化合物，其活性形式由公式（A）表示，并且可以注射到关节腔中，该关节腔是疾病的受影响部位，并且可以在关节腔中积累，以持续发挥其药理作用，以改善软骨疾病而不产生任何副作用。本发明提供的化合物由公式（I）表示：（其中所有符号在说明中定义），是一种可以实现上述目的的化合物。即使以有效量给予该化合物以展示软骨再生活性，该化合物也不会对心血管系统产生任何副作用，因此非常有用作为软骨疾病的安全有效的预防和/或治疗剂。由于使用该化合物制成的悬浮液可以注射而无需切开受影响部位，因此可以减轻患者的负担，是一种非常有用的药物剂。
• US9085523B2
  申请人：——

  公开号：US9085523B2

  公开（公告）日：2015-07-21
• CN115611821
  申请人：——

  公开号：——

  公开（公告）日：——
• COMPOUND FOR TREATING CARTILAGE DISORDERS
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP2740724B1

  公开（公告）日：2016-12-28